SomnoMed Ltd (ASX: SOM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

SomnoMed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $84.28 million
P/E Ratio 136.99
Dividend Yield 0.00%
Shares Outstanding 216.11 million
Earnings per share -0.092
Dividend per share N/A
Year To Date Return 9.84%
Earnings Yield 0.73%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • SomnoMed Ltd (ASX: SOM)
    Latest News

    In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
    Earnings Results

    2 small ASX healthcare shares sprouting green after FY24 results

    Healthcare stocks continue to show strong results in FY24.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Cardno, Mesoblast, Perseus, and Somnomed shares are dropping today

    These ASX shares are having a tough hump day. But why?

    Read more »

    Share Market News

    What's behind the sleepy Somnomed (ASX:SOM) share price?

    The Somnomed share price dipped more than 2% lower today. We look at the company's current position and consider the…

    Read more »

    Share Gainers

    Rhinomed (ASX:RNO) share price tries following Starpharma's path to COVID glory

    The Rhinomed Ltd (ASX: RNO) share price surged to a six-month high as it takes a leaf out of the…

    Read more »

    a woman
    Share Market News

    SomnoMed share price rises after reporting positive earnings

    The SomnoMed Limited (ASX: SOM) share price has risen today after the company reported its half-year earnings.

    Read more »

    a woman
    52-Week Highs

    Why the SomnoMed share price is at a 52-week-high

    The SomnoMed Limited (ASX: SOM) share price has closed at a 52-week-high after making a spectacular recovery over the last…

    Read more »

    a woman
    Share Gainers

    ALL ORDINARIES finishes higher Tuesday: 8 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished higher on Tuesday.

    Read more »

    a woman
    Share Market News

    Is the Somnomed share price a turnaround story?

    Somnomed Limited (ASX: SOM) has restructured its sales and reports its outlook is "very positive".

    Read more »

    a woman
    Share Market News

    Is SomnoMed Limited a turnaround story?

    SomnoMed Limited (ASX: SOM) reported its quarterly results today.

    Read more »

    a woman
    Share Market News

    Trading update: Here's why the SomnoMed share price is falling today

    SomonMed Limited (ASX: SOM) is under pressure after a customer folded.

    Read more »

    a woman
    Share Fallers

    The Medical Developments share price is now down 49% over the past year

    Will Penthrox manufacturer Medical Developments International Ltd (ASX:MVP) get FDA approval in the US?

    Read more »

    a woman
    Share Fallers

    Why the SomnoMed Limited share price is falling today

    The SomnoMed Limited (ASX: SOM) share price is down nearly 50% in one year.

    Read more »

    SOM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About SomnoMed Ltd

    SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, SomTabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the onlyreportable segment. Substantial revenue is realized from the European region.

    SOM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    03 Oct 2024 $0.39 $-0.01 -2.50% 120,872 $0.40 $0.40 $0.39
    02 Oct 2024 $0.40 $0.00 0.00% 75,201 $0.43 $0.43 $0.40
    26 Sep 2024 $0.40 $0.00 0.00% 75,322 $0.41 $0.44 $0.40
    25 Sep 2024 $0.40 $-0.03 -6.98% 23,902 $0.42 $0.42 $0.40
    24 Sep 2024 $0.43 $0.02 4.85% 53,092 $0.41 $0.43 $0.41
    23 Sep 2024 $0.41 $-0.03 -6.82% 82,144 $0.44 $0.44 $0.41
    19 Sep 2024 $0.44 $0.03 7.32% 2,888 $0.42 $0.44 $0.42
    18 Sep 2024 $0.41 $-0.04 -8.89% 10,587 $0.41 $0.41 $0.41
    17 Sep 2024 $0.45 $0.01 2.27% 46,968 $0.41 $0.45 $0.41
    16 Sep 2024 $0.44 $0.00 0.00% 3,268 $0.41 $0.44 $0.41
    13 Sep 2024 $0.44 $-0.01 -2.22% 17,144 $0.45 $0.45 $0.43
    12 Sep 2024 $0.45 $0.03 7.06% 65,962 $0.43 $0.47 $0.43
    11 Sep 2024 $0.43 $0.00 0.00% 16,215 $0.39 $0.43 $0.39
    10 Sep 2024 $0.43 $0.00 0.00% 17,322 $0.40 $0.43 $0.40
    09 Sep 2024 $0.43 $0.00 0.00% 8,007 $0.42 $0.43 $0.41
    06 Sep 2024 $0.43 $0.00 0.00% 50,539 $0.41 $0.43 $0.40
    05 Sep 2024 $0.43 $0.00 0.00% 8,802 $0.42 $0.43 $0.42
    04 Sep 2024 $0.43 $0.00 0.00% 15,189 $0.41 $0.43 $0.41

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Sep 2024 Karen Borg Buy 12,238 $5,384
    On-market trade. share approximately
    09 Sep 2024 Karen Borg Buy 25,593 $10,749
    On-market trade. share approximately
    01 Jul 2024 Karen Borg Issued 575,000 $155,250
    Issue of options.
    01 Jul 2024 Amrita Blickstead Issued 575,000 $155,250
    Issue of options.
    28 Jun 2024 Amrita Blickstead Issued 750,000 $189,375
    Issue of options.
    28 Jun 2024 Karen Borg Issued 750,000 $189,375
    Issue of options.
    08 May 2024 Karen Borg Issued 476,191 $100,000
    Rights issue.
    08 May 2024 Gaetano (Guy) Russo Issued 952,381 $200,000
    Rights issue.
    08 May 2024 Amrita Blickstead Issued 952,381 $200,000
    Rights issue.
    08 May 2024 Hamish Corlett Issued 35,143,697 $7,380,176
    Rights issue.
    08 May 2024 Michael Gordon Issued 111,971 $23,513
    Rights issue.
    22 Feb 2024 Neil Verdal-Austin Transfer 160,000 $64,000
    Off-market transfer. Assuming off market transfer of shares
    22 Feb 2024 Neil Verdal-Austin Transfer 160,000 $64,000
    Off-market transfer. Assuming off market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Gordon Non-Executive Director Aug 2020
    Mr Gordon is a Director of K Sleep Holdings Pty Limited Koala, a direct to consumer household goods retailer. Michael was previously the CFO of Different Technologies, a property technology company, and before that Michael was CFO of Rokt, a marketing technology company with more than US$300m in revenue. Prior to Rokt, Michael was the Group CFO and MD of Group Services for Greenlit Brands Pty Limited. Greenlit Brands grew from a turnover of A$250m (Freedom) to a A$2.4 billion vertically integrated retailer based in Australia and New Zealand and included the brands, Freedom, Snooze, Fantastic, Plush, OMF, Best & Less and Harris Scarfe. Prior to Greenlit Brands, Michael spent ten years with PricewaterhouseCoopers in South Africa, the United Kingdom and Australia specialising in the retail and pharmaceutical industries with experience in audit, taxation M&A and IPOs.
    Mr Gaetano (Guy) Alfred Gerrard Russo Non-Executive ChairmanNon-Executive Director Aug 2020
    Mr Russo is an accomplished business leader with a commercial and customer focussed background working in Australia and internationally. In addition to Chairman of SomnoMed he is Chairman of Guzman y Gomez Mexican Kitchen (GYG), Australia's growing restaurant business. Previously, Guy has served as CEO, Wesfarmers Department Store Division (Kmart & Target); Managing Director, Kmart Australia & NZ; President, McDonald's Greater China; CEO McDonald's Australia Ltd and Chairman of onald McDonald House Children's Charities. Guy is perhaps well known in Australia for his leadership in turning Kmart into the largest and profitable retail department store in the country. He has been a member of YPO since 2006, served as a member of the Business Council of Australia, and won industry awards for leadership in diversity in employment.
    Mr Hamish James Corlett Non-Executive Director May 2018
    Mr Corlett is a founder and director of TDM Growth Partners, a leading private investment firm in long term investments in companies globally. TDM made its first investment in SomnoMed in April 2010 and has been a substantial shareholder in the Company since October 2012. Prior to TDM, Hamish worked as an Investment Manager at Caledonia Investments, a global fund manager. Hamish also worked in London in an operating role for an ecommerce start up and in Sydney at Caliburn Partnership (now Greenhill) in corporate advisory. Hamish is also a Non-Executive Director QBiotics Group Limited.
    Ms Amrita Blickstead Executive DirectorJoint CEO Feb 2024
    Ms Blickstead is the former Chief Operating and Marketing Officer at eBay Australia. The foundation of her career began in medical devices as a Biomedical Engineer at Cochlear and Ventracor .
    Ms Karen Borg Executive DirectorJoint CEO Feb 2024
    Ms Borg has a career in the medical devices sector. She has led businesses within Johnson & Johnson Medical and ResMed, as well as health and industry organizations for state and federal government. Most recently, she was the CEO of Catholic Healthcare.
    Mr Terence Anthony Flitcroft Company Secretary
    -
    Darren Collins Chief Financial Officer
    -
    Terence Anthony Flitcroft Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 40,281,683 40.66%
    National Nominees Limited 14,541,201 14.68%
    Equity Plan Services Pty Ltd 4,617,834 4.66%
    Citicorp Nominees Pty Limited 4,079,645 4.12%
    Dottie Investments Pty Ltd 3,650,487 3.68%
    Howarth PAF Pty Ltd <The Howarth Foundation A/C> 2,156,722 2.18%
    Belgove Pty Ltd 2,053,265 2.07%
    Ginga Pty Ltd 1,739,045 1.75%
    BNP Paribas Nominees Pty Ltd <ACF Clearstream A/C> 1,703,127 1.72%
    Bond Street Custodians Ltd <Salter – D79836 A/C> 1,600,000 1.61%
    J P Morgan Nominees Australian Pty Limited 1,217,842 1.23%
    P Neustadt Holdings Pty Ltd <Belgove Super Fund A/C> 1,082,171 1.09%
    Timbina Pty Ltd <Timbina Super Fund A/C> 1,073,764 1.08%
    REM Medical Pty Ltd <Cocoon Super Fund A/C> 876,135 0.88%
    Golden Words Pty Ltd 775,399 0.78%
    Honne Investments Pty Limited 600,000 0.61%
    Thirty Sixth Vilmar Pty Ltd 591,993 0.60%
    The Mulloon Institute Ltd 533,048 0.54%
    Howarth PAF Pty Ltd <Howarth Charitable Fund A/C> 523,771 0.53%
    Mr Edward Palmisano 484,631 0.49%

    Profile

    since

    Note